Wanbury Ltd has launched commercial production of a new anaesthetic Active Pharmaceutical Ingredient (API) at its Tanuku facility. The rollout is projected to generate ₹180 million in Q4 FY2025-26 revenues. This milestone strengthens India’s pharmaceutical supply chain and positions Wanbury for growth in regulated global markets.
Show moreStay Ahead – Explore Now! Brahmaputra Infrastructure Secures ₹466.2M Order, Strengthening Growth Pipeline
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
